WO2015095881A1 - Pet food composition having probiotic bifidobacterium animalis - Google Patents
Pet food composition having probiotic bifidobacterium animalis Download PDFInfo
- Publication number
- WO2015095881A1 WO2015095881A1 PCT/US2014/071962 US2014071962W WO2015095881A1 WO 2015095881 A1 WO2015095881 A1 WO 2015095881A1 US 2014071962 W US2014071962 W US 2014071962W WO 2015095881 A1 WO2015095881 A1 WO 2015095881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kibble
- coated
- fat
- ahc
- coating
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 61
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 61
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 61
- 241001134770 Bifidobacterium animalis Species 0.000 title claims description 31
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 title description 56
- 235000013305 food Nutrition 0.000 title description 50
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 164
- 238000000576 coating method Methods 0.000 claims abstract description 105
- 235000011187 glycerol Nutrition 0.000 claims abstract description 82
- 239000011248 coating agent Substances 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 235000013406 prebiotics Nutrition 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000003925 fat Substances 0.000 description 122
- 235000019197 fats Nutrition 0.000 description 122
- 241000894006 Bacteria Species 0.000 description 52
- 239000010410 layer Substances 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 30
- 239000000654 additive Substances 0.000 description 28
- 241000287828 Gallus gallus Species 0.000 description 27
- 235000013330 chicken meat Nutrition 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 26
- 239000003995 emulsifying agent Substances 0.000 description 22
- 239000002994 raw material Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 16
- 235000012054 meals Nutrition 0.000 description 16
- 230000008901 benefit Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 9
- 235000013372 meat Nutrition 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 239000003760 tallow Substances 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 235000015278 beef Nutrition 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 229920001202 Inulin Polymers 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 7
- 229940029339 inulin Drugs 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000004014 plasticizer Substances 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000005086 pumping Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 235000019605 sweet taste sensations Nutrition 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000008199 coating composition Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- -1 fats of avian Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 description 3
- 241000335053 Beta vulgaris Species 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 239000004470 DL Methionine Substances 0.000 description 3
- 230000009946 DNA mutation Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 235000021186 dishes Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 108091005708 gustatory receptors Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 235000005135 Micromeria juliana Nutrition 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000002114 Satureja hortensis Species 0.000 description 2
- 235000007315 Satureja hortensis Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 210000005205 gut mucosa Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000013097 stability assessment Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019735 Meat-and-bone meal Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical class OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/20—Shaping or working-up of animal feeding-stuffs by moulding, e.g. making cakes or briquettes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6406—Glycerol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Definitions
- the present invention relates to pet food compositions comprising probiotics.
- Probiotics are considered to be preparations of bacteria, either viable or dead, their constituents such as proteins or carbohydrates, or purified fractions of bacterial ferments that promote mammalian health by preserving and promoting the natural microflora in the GI tract, and reinforcing the normal controls on aberrant immune responses. It is believed by some that probiotic bacteria are more effective when derived from the species, or a closely related species to the individual intended to be treated. Therefore, there is a need for probiotic strains derived from companion animals to be used for companion animals that are different to those derived from humans.
- a coated kibble which comprises a kibble; a coating on the kibble comprising a fat; a coating on the kibble comprising a probiotic; wherein the kibble comprises internal glycerin.
- a method for producing a coated kibble which comprises extruding a kibble having internal glycerin; and coating the kibble with Bifidobacterium animalis.
- FIG. 1 is a schematic, cross-sectional view of an exemplary coated food product.
- FIG. 2 is a graph demonstrating stability of AHC-7 probiotic at 23 °C in presence of glycerin and non-glycerin systems.
- FIG. 3 is a graph demonstrating stability of AHC-7 probiotic at 40°C in presence of glycerin and non-glycerin system.
- FIG. 4 is a graph demonstrating the stability of AHC-7 probiotic in the presence and absence of externally coated glycerin.
- FIG. 5 is a graph demonstrating the stability of AHC-7 bacteria in the presence and absence of internal glycerin.
- FIG. 6 is a graph demonstrating AHC-7 stability on kibble in the presence and absence of internal glycerin at two different levels.
- the present invention comprises a food product; for example, a kibble comprising glycerin and a probiotic, such as Bifidobacterium animalis (AHC-7) coated on the outside of the kibble.
- AHC-7 Bifidobacterium animalis
- glycerin was coated on the outside of the kibble along with AHC-7, such that the AHC-7 was in contact with the glycerin.
- the glycerin was incorporated into the kibble and AHC-7 was applied to the kibble surface, the AHC- 7 was stable.
- "companion animal” means a domestic animal, for example a domestic canine, feline, rabbit, ferret, horse, cow, or the like.
- mutants thereof includes derived bacterial strains having at least 93% homology, at least 96% homology, or at least 98% homology to the 16s-23s intergenic spacer polynulceotide sequence of a referenced strain, but otherwise comprising DNA mutations in other DNA sequences in the bacterial genome.
- DNA mutations includes natural or induced mutations comprising at least single base alterations including deletions, insertions, transversions, and other DNA modifications known to those skilled in the art, including genetic modification introduced into a parent nucleotide or amino acid sequence while maintaining at least 50% homology to the parent sequence.
- the sequence comprising the DNA mutation or mutations may have at least 60%, at least 75%, or at least 85% homology with the parental sequence.
- sequence "homology” can be determined using standard techniques known to those skilled in the art. For example, homology may be determined using the on-line homology algorithm "BLAST" program, publicly available at http://www.ncbi.nlm.nih.gov/BLAST/.
- SEQ. ID NO. 2 Primer sequences for 16s-23s DNA sequence analysis.
- the table below indicates Bifidobacterium animalis strains that can be used in the present invention.
- the bacterial strains are deposited with the National Collections of Industrial Food and Marine Bacteria (NCIMB), Aberdeen, UK.
- Probiotics are micro-organisms, either viable or dead, processed compositions of microorganisms, their constituents such as proteins or carbohydrates, or purified fractions of bacterial ferments that beneficially affect a host.
- the general use of probiotic bacteria is in the form of viable cells. However, it can be extended to non- viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This may include thermally killed micro-organisms, or micro-organisms killed by exposure to altered pH or subjected to pressure.
- probiotics is further intended to include the metabolites generated by the micro-organisms used in the present invention during fermentation, if they are not separately indicated.
- probiotic also includes bacteria, bacterial homogenates, bacterial proteins, bacterial extracts, bacterial ferment supernatants, and mixtures thereof, which perform beneficial functions to the host animal when given at a therapeutic dose.
- strains of Bifidobacterium animalis obtainable by isolation directly from resected and washed GI tract of mammals are adherent to the GI tract, following feeding of viable bacterial cells, and are also significantly immunomodulatory when fed to animals in viable, non- viable or fractionated form.
- the Bifidobacterium animalis obtainable by isolation from resected and washed GI tract closely associates with the gut mucosal tissues. Without further being bound by theory, this is believed to result in the probiotic Bifidobacterium animalis of the present invention generating alternative host responses that result in its probiotic action.
- probiotic bacteria obtainable by isolation from resected and washed GI tract can modulate the host's immune system, via direct interaction with the mucosal epithelium and the host's immune cells.
- This immunomodulation in conjunction with the traditional mechanism of action associated with probiotic bacteria, i.e. the prevention of pathogen adherence to the gut by occlusion and competition for nutrients, results in the Bifidobacterium animalis of the present invention being highly efficacious as a probiotic organism.
- the Bifidobacterium animalis of the present invention obtainable by isolation from resected and washed canine GI tract, have in vitro anti-microbial activity against a number of pathogenic bacterial strains/species, as measured by zones of inhibition or bacterial growth inhibition assays known to those skilled in the art. Without being bound by theory, it is believed that this in vitro anti-microbial activity is indicative of potential probiotic activity in vivo in animals, such as canines and felines.
- the bacteria of the present invention may have in vitro anti-microbial activity against Salmonella typhimurium, Listeria monocytogenes, Listeria innocua or Eschericia coli, or combinations thereof.
- the anti-microbial activity of the Bifidobacterium animalis bacteria of the present invention may be the result of a number of different actions by the Bifidobacterium animalis bacteria herein. It has previously been suggested in the art that several strains of bacteria isolated from fecal samples exert their probiotic effect in the GI tract following oral consumption, by preventing the attachment of pathogenic organisms to the gut mucosa by occlusion. This requires oral consumption of "live" or viable bacterial cells in order for a colony of bacteria to be established in the gut.
- the Bifidobacterium animalis used in the present invention while exerting some probiotic effect due to occlusion if given in a viable form, may deliver a substantial probiotic effect in either the viable or non- viable form due to the production during fermentation in vitro of a substance or substances that either inhibit the growth of or kill pathogenic micro-organisms, and/or alter the host animal's immune competence.
- This form of probiotic activity is desirable, as the bacteria of the present invention can be given as either viable or non-viable cultures or purified fermentation products and still deliver a beneficial therapeutic effect to the host animal.
- the Bifidobacterium animalis bacteria of the present invention are able to maintain viability following transit through the GI tract.
- the bacteria of the present invention maintain viability after suspension in a media having a pH of 2.5 for 1 hour.
- “maintain viability” means that at least 25% of the bacteria initially suspended in the test media are viable using the plate count method known to those skilled in the art. In certain embodiments, “maintain viability” means that at least 50% of the bacteria initially suspended are viable. It is desirable for the bacteria of the present invention to maintain viability following exposure to low pH as this mimics the exposure to gastric juices in the stomach and upper intestine in vivo following oral consumption in animals.
- the bacteria of the present invention have a growth of at least 33% when in the presence of at least 0.5% porcine bile salts. In further embodiments, the bacteria of the present invention have a growth of at least 33% when in the presence of at least 1 % porcine bile salts. Without being bound by theory it is believed that the bacteria of the present invention, capable of growth in the presence of at least 0.5% porcine bile salts, are able to survive the conditions present in the intestine. This is thought to be a result of the addition of porcine bile to the culture medium mimicking the conditions of the intestine. Further still, the Bifidobacterium animalis bacteria used in the present invention may have significant adhesion to gut epithelial cells in vitro.
- significant adhesion means at least 4% of the total number of bacteria co-incubated with the epithelial cells in vitro adhere to the epithelial cells; or in certain embodiments, at least 6% of bacterial cells co-incubated adhere to epithelial cells in vitro.
- gut epithelial cell adherence in vitro is indicative of the bacteria's ability to colonize the GI tract of an animal in vivo.
- the 16s-23s intergenic polynucelotide sequence is known to those skilled in the art as the sequence of DNA in the bacterial genome that can be used in order to identify different species and strains of bacteria.
- the strain of Bifidobacterium animalis has a 16s-23s intergenic polynucleotide sequence that has at least 93%, at least 96%, or at least 99% homology with the polynucleotide sequence according to SEQ. ID NO. 1.
- the strain of bacteria according to the present invention has a 16s-23s polynucelotide sequence according to SEQ. ID NO. 1.
- the strain of bacteria according to the present invention is Bifidobacterium animalis strain NCIMB 41199 (AHC-7), or a mutant thereof.
- the strain of bacteria of the genus Bifidobacterium animalis obtainable by isolation from resected and washed canine gastrointestinal tract can be used to deliver probiotic benefit following oral consumption in animals, such as companion animals or humans. This probiotic benefit generally maintains and improves the overall health of the animal.
- Non- limiting elements of animal health and physiology that benefit, either in therapeutically relieving the symptoms of, or disease prevention by prophylaxis include inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune systems), diarrheal disease, antibiotic associated diarrhea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, amyloidosis, rheumatoid arthritis, arthritis, joint mobility, diabetes mellitus, insulin resistance, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, weight gain, excessive adipose tissue accumulation, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier infection, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system, hepatic disease, ischemia, nutritional disorders
- inflammatory disorders including autoimmune disease and inflammation may be detected and monitored using in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
- in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
- the method of use of the Bifidobacterium animalis bacteria of the present invention typically involves oral consumption by the animal. Oral consumption may take place as part of the normal dietary intake, or as a supplement thereto. The oral consumption typically occurs at least once a month, if not at least once a week, or at least once per day.
- the Bifidobacterium animalis bacteria used in the present invention may be given to the companion animal in a therapeutically effective amount to maintain or improve the health of the animal.
- the term "therapeutically effective amount” with reference to the bacteria means that amount of the bacteria sufficient to provide the desired effect or benefit to a host animal in need of treatment, yet low enough to avoid adverse effects such as toxicity, irritation, or allergic response, commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
- the specific "therapeutically effective amount” will vary with such factors as the particular condition being treated, the physical condition of the user, the duration of the treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the carrier employed, the solubility of the dose form, and the particular dosing regimen.
- the bacteria may be given to the companion animal at a dose of from about 10 4 to about 10 14 CFU per day or from about 10 6 to about 10 12 CFU per day.
- a kibble in certain embodiments may contain at least 0.001 % of from about 10 4 to about 10 12 CFU/g of the Bifidobacterium animalis.
- the Bifidobacterium animalis bacteria can be given to the animal in either viable form, or as killed cells, or distillates, isolates or other fractions of the fermentation products of the bacteria of the present invention, or any mixture thereof.
- the Bifidobacterium animalis bacteria, or a purified or isolated fraction thereof, are used to prepare a composition intended to maintain or improve the health of an animal.
- the composition may be part of the normal dietary intake, or a supplement. Where the composition comprises part of the normal dietary intake, the composition may be in the form of a pet food such as biscuits or kibbles.
- FIG. 1 is a cross-sectional view of an exemplary coated kibble 18, a kibble 10 coated with one or more distinct coatings 12, 14, and 16. Any one or all coatings may cover the surface of the kibble completely or partially as shown by continuous or dotted lines in the figure.
- the selection and combination of coating 12, 14, and 16 may be useful in improving the taste, texture, or appearance of a coated kibble 18, which is the combined kibble 10 with one or more of coatings 12, 14, and 16.
- any one or any combination of coatings 12, 14, and 16 may be present in different embodiments of the invention. At least one of the coatings 12, 14 and 16 will contain AHC-7.
- AHC-7 can be applied on kibble either through dry or liquid medium consisting of flavor system in combination with other dry or liquid ingredients at different ratios.
- the coatings 12, 14, and 16 may be distinct. That is, there may be insignificant mixing of the coatings after they are applied, with distinct layers of different coatings present. By insignificant mixing, it is recognized that there will be some interaction at the interface between different coatings, but there is not commingling of the coatings, such that, over time, there appears to be only one coating rather than two or more distinct coatings. Additional coatings, that is, more than three coatings, may be used. In FIG.
- Kibble 10 has a round shape; however, it should be understood that the food is not limited in shape and may have any shape or dimension desired for the product, taking into account both functional aspects of the volume and surface area of the food pieces and aesthetic considerations. Kibble 10 may be one component of a food product that comprises kibble of two or more different shapes, sizes, and/or compositions.
- Kibble 10 may be a dried food, having a moisture content of less than about 20%, less than about 15%, less than about 12%, less than about 9%, or less than about 5%, water by weight of the kibble. Low moisture content may contribute to the shelf- stability of kibble 10, in particular, the resistance of kibble 10 to microbial growth over time. Kibble 10 comprises a plasticizer, such as glycerin. Glycerin has a low water activity (Aw), less than or equal to about 0.1. The glycerin can be added either internally in a kibble (internal glycerin) or externally as an enrobing agent (external glycerin).
- glycerin levels as low as 1 % have a detrimental effect on the bacteria. Glycerin levels added internally to a kibble have shown little or no detrimental effect on the bacteria.
- the glycerin is either injected into an extruder via the pre-conditioner cylinder or mixed with the ration.
- the glycerin is coated on the kibble surface by any spraying and/or mixing method. The temperature of the glycerin is maintained, such that it is fluid enough for pumping and spraying.
- Kibble 10 internally comprises glycerin in certain embodiments at an amount from about 0.5% to about 35%, about 1% to about 20%, or about 5% to about 15%, by weight of the kibble, including any coatings.
- the inclusion of glycerin within kibble 10 at a certain level may make the kibble softer and easier to chew than a kibble of comparable moisture content with no glycerin.
- kibble with glycerin inside the kibble may have a greater softness (lower measured compressive force) than a kibble with no internal glycerin by a factor of 2 or even 3, depending on the final moisture content, which in certain embodiments can be from about 0.1 aw to about 0.5 aw.
- glycerin may provide a sweet taste to the kibble.
- this sweet taste may be undesirable if the ratio is not balanced properly.
- the inclusion of an acid such as formic acid, acetic acid, propionic acid, butyric acid, lactic acid, sorbic acid, fumaric acid, malic acid, tartaric acid, citric acid, phosphoric acid, ascorbic acid, sulfuric acid, hydrochloric acid, or combinations thereof, may reduce an alteration in taste associated with a plasticizer.
- the acid may be present at an amount greater than 0% and less than about 2%, or less than about 1.5% of the kibble.
- the acid is incorporated into the glycerin, and the glycerin is added to the kibble as described above, that is, added into the kibble. In some embodiments, the acid is added to the kibble (internally or externally) separately from glycerin. In some embodiments, glycerin is used without adding offsetting amounts of acid or other sour-tasting ingredients (e.g., the food is presented with a sweet taste, rather than a savory taste). Some dogs, for example, may prefer a sweet taste, or glycerin may be used with a food intended to have a sweet taste.
- a kibble can be any suitable composition that is ingestible by a human or an animal and that provides nutritional value to the human or animal.
- the kibble can be coated or uncoated prior to being treated as disclosed here.
- a kibble generally will be a basal food composition having a nutritionally balanced mixture of proteinaceous and farinaceous ingredients.
- the kibble can be baked, extruded, pelleted, or formed.
- Such forms of kibble, and methods for their production, are well known to those of skill in the art of food manufacturing. Extrusion and extrusion cooking, for example, are described on pages 794-800 of the Encyclopedia of Food Science and Technology, Volume 2 (Y. H. Hui, ed., John Wiley & Sons, Inc. 1992).
- a kibble is not limited to a particular composition.
- a kibble may be a nutritionally complete and balanced animal diet which provides all essential nutrients to sustain life (with the exception of water).
- Nutritionally complete and balanced kibbles may meet consensus nutrient profiles, such as AAFCO standards for dog or cat food.
- a kibble may be a treat or supplement that is not nutritionally balanced, but may provide some nutritive value (e.g., calories). In such instances, the kibble may be used as a treat or supplement rather than a primary diet, or the kibble may be mixed with different particles so that the mix of kibble and other foodstuff is nutritionally complete and balanced.
- the kibble may be mixed with nutritionally different kibble, or with fruit or vegetable pieces (such as carrot pieces, pea pieces, soy morsels, dried fruits, etc.), or with meat pieces (such as dried or preserved meats, including jerky, or otherwise prepared or preserved meats), or with tablets, capsules, or pellets comprising desired nutrients, or combinations thereof, such that the mixture is nutritionally complete and balanced.
- a kibble can be any suitable form, such as bite-size or pellet form of any shape.
- Coating 12 is applied externally to the formed kibble.
- Coating 12 is a surface coating on or near the outside of kibble 10, recognizing that some of coating 12 may migrate into kibble 10 at the interface between kibble 10 and coating 12.
- the coating 12 may comprise fat; and may provide assistance in ensuring adherence of dry matrix, which could be a flavor system with or without probiotic.
- the term "fat” refers to any edible grade fat or lipid, including fats of avian, animal, plant, or manufactured origin, including, but not limited to, crude or refined fats.
- Typical animal origin fats include, for example, animal tallow, choice white grease, lard, milk-derived fats such as butter oil, and fat typically contained in cheese.
- Typical fats of vegetable origin include coconut oil, soybean oil, and corn oil.
- Typical fats of avian origin include fats derived from the tissue of chickens, turkeys, ducks, and geese, for example.
- Applying fat coating over a kibble containing glycerin may reduce the absorption of fat coating into kibble. Keeping fat coating on the surface of kibble may help enhance the flavor and/or mouth feel of the food at relatively lower levels of add-on fats, because a greater proportion of the fat is available at the interface between the food and the mouth when the food is consumed.
- Exemplary fats include poultry fat, such as chicken fat, and beef tallow. Fat coating may be present in an amount from about 1% to about 15%, about 6% to about 8%, or about 11% to 13%, by weight of the coated kibble.
- a hydrophobic fat coating may help retain moisture within the food; that is, to keep the food from losing additional moisture during transportation and storage, especially in dry conditions (relative humidity of less than about 35%).
- a heavier fat coating may be beneficial on foods comprising glycerin in the kibble, as compared to foods which do not comprise a plasticizer in the kibble.
- coated kibble with a plasticizer in the kibble may have a fat coating which is about 11% to about 13% of the weight of the coated kibble.
- the food product is a complete and nutritionally balanced pet food, it may be desirable to keep the total fat content of the food, including any fat in the kibble and the fat in all coating layers, to less than about 25% or less than about 20%, of the weight of the coated kibble, to ensure that other nutrients are present in suitable proportions.
- Fat coating may comprise one or more structurants.
- the structurant may alter the concentration and/or crystalline order of the solids in fat coating.
- the structurant may alter other physiochemical properties, such as viscosity or density, of the fat coating.
- the structurant may prevent or reduce smearing of fat coating as coated kibble is processed, shipped, and used.
- particles of coated kibble may interact with each other, manufacturing equipment (including packaging equipment), packaging, serving utensils, serving dishes, hands, and the like, and a structurant may help keep fat coating firm and resilient, so that the coating is not displaced or transferred away from the food during these interactions.
- a high melting point (greater than or equal to 60°C) fat or edible wax may serve this purpose.
- a fat may be preferable to an edible wax for mouth feel or taste.
- Fat coating may comprise between about 1 % to about 10%, or between about 2% to about 4%, of the structurant by weight of the fat coating composition.
- the structurant may comprise a gum, such as xanthan gum or guar gum, modifications thereof, or combinations thereof.
- the structurant may comprise an emulsifier.
- the emulsifier may provide a polar component that improves the interaction between fat coating and other, hydrophilic coatings, if hydrophilic coatings are used.
- the emulsifier may contribute to the transfer of fat from the food to the mouth, and the distribution of fat within the mouth, via interactions with aqueous saliva.
- the emulsifier may both help retain fat coating on the kibble surface, like a glaze, and improve the taste and/or mouth feel of the food when it is eaten.
- an emulsifier may be desirable even if fat coating (e.g., before the addition of an emulsifier) is not an emulsion.
- the emulsifier may be present in an amount between about 1% to about 10% or between about 2% to about 5%, by weight of the fat coating composition.
- an emulsifier is applied over the fat coating.
- the emulsifier may be present in an amount between about 0.1 % to about 5% or between about 1% to about 3%, by weight of the fat coating composition.
- Any edible emulsifier may be used, for example, lecithins, polyglycerol esters, or combinations thereof.
- Some compounds, such as high melting temperature (60°C to 80°C) mono- and/or di- glycerides may provide structural benefits and provide a polar component to fat coating.
- Such structurants may also increase the total melting point of the fat system (fat+structurant), depending on the level of the structurant in the fat system.
- Suitable mixes of glycerides are commercially available under the tradename Trancendim®, from Caravan Ingredients of Lenexa, Kans., USA.
- a suitable mix of glycerides, for example, is Trancendim (Registered trademark) 180 or Trancendim® 130.
- the structurant may be present at between about 0.1% to about 10% by weight of the fat coating composition.
- the structurant may be blended into the fat coating, such that there is a single coating of a composition comprising a fat and a structurant.
- the structurant may be applied separately as an overlay coating on the fat coating.
- a coating containing the probiotic 14 may be applied over the coating 12, which may be a fat coating.
- the AHC-7 coating describes the addition of AHC-7 to a kibble.
- AHC-7 is applied by weight to a minimum level of about 10 cfu/g, or from about 10 6 cfu/g to about 10 8 cfu/g or from about 10 8 cfu/g to about 10 10 cfu/g.
- AHC7 may also be applied to kibble matrix through other carriers like fatty acids, protein, monoglycerides, polysaccharides (carbohydrates, sugars, hydrocolloids etc.).
- Coating 16 may comprise dry or liquid additives. If fat coating 12 comprises an emulsifier, the emulsifier may enable the layering of liquid additives. The liquid additives may remain associated with fat coating 12 because of the emulsifier, but remain at the surface of fat coating 12 because of the incompatibility of the liquid additive (mostly hydrophilic) and the fat (mostly hydrophobic). This may be particularly, but not exclusively, helpful with liquid palatants, since it is most efficient to apply palatants on the outermost coating of the food so they are readily available to taste receptors in the mouth when the food is eaten.
- a liquid additive applied over fat coating 12 will be attracted to the surface but disinclined to pass through or mix with fat coating 12, the liquid additive should be more available at the surface of the food.
- Dry additives including dry palatants or other dry ingredients, may be applied over fat coating 12 or over a liquid additive applied over fat coating 12.
- dry additives will acceptably adhere to either a fat- moistened or liquid-moistened surface.
- Some specific dry additives will have chemical properties which make it most advantageous to apply them directly to fat coating 12 or after a layer of liquid additives is applied over fat coating 12, or even to apply the dry additives as part of fat coating 12 or in the form of a liquid additive (as by dissolving or mixing the dry additive in water before applying it to the food).
- the ratio, by weight, of fat to a liquid additive may, in some embodiments, be between about 0.3 to about 8. Other ratios are feasible.
- Coating 16 may comprise emulsifiers to lower the surface energy of the coated kibble, and reduce or prevent the kibbles from sticking together, such that the kibbles can be freely dispensed and easily eaten as distinct pieces. Of course, it may sometimes be desirable for the kibble to clump, as if forming a snack bar or treat from the coated kibble.
- Adding the fat coating may seal in moisture and help maintain softness over time.
- the softness of the food is increased by at least 20%, or by at least 40%, by using the method.
- the softness of the food declines by no more than 25% when stored for 6 months at 18°C to 22°C and 40% to-60% relative humidity. Softness can be measured using the food softness test method described below. Softness may be helpful in that the process of masticating softer food may stimulate salivation more than masticating crunchy food, which may help transfer fat and palatants from the food to taste receptors in the mouth, and, therefore, improve the palatability of the food.
- the food softness test is a compressive strain test. Using a calibrated Instron compression tester (or equivalent) with a 1KN load cell and plate/anvil set-up, place a piece of kibble as flat as possible at the point of testing (this will vary depending on the kibble shape being tested).
- the anvil is a cylindrical, flat-bottomed test fixture and must be larger in diameter than the kibble being tested. Set up the tester to compress the kibble to 33.33% of its original height. Repeat for at least 25 kibble pieces for each type of kibble tested. Sweep away any debris or residue between samples.
- Coatings as disclosed may be used to alter the texture (mouth feel and moistness perception) of a kibble.
- the texture can be measured by measuring the force required to crush the kibble.
- the force required to crush the kibble simulates chewing.
- the kibbles may be lubricious with a crispy texture, and may have a softness value from about 4 to about 12 kgf, from about 3 to about 9 kgf, or from about 3.5 to about 5.5 kgf.
- Kibble with a soft texture may contain glycerin in certain embodiments internally, as discussed previously at an amount from about 0.5% to about 35%, about 1% to about 20%, or about 5% to about 15%, by weight of the kibble, and the texture can be measured as softness or chewiness, as described in the food softness test.
- Soft kibbles may have a "softness" value from about 1 kgf/cm 2 to about 9 kgf/cm 2 , from about 3 kgf/cm 2 to about 8 kgf/cm 2 , or from about 3 kgf/cm 2 to about 7 kgf/cm 2 .
- the texture of the hard kibble can also be characterized with the Young's modulus of the kibble (force per area of kibble, kgf/cm 2 ).
- the maximum pressure may be from about 12 to about 35 kgf/cm 2 , or from about 12 to about 20 kgf/cm 2 .
- Soft kibbles may show a Young's Modulus of about 1 to about 15 kgf/cm 2 , or about 2 to about 7 kf/cm 2 , or about 2.5 to about 5 kgf/cm 2 . Kibbles with different textures and/or coatings can be blended in any desired ratio to provide texture variety for the pet.
- One possible advantage of a coating or series of coatings as disclosed is to increase the amount of fat that stays on the surface of the kibble.
- the level of fat on the surface may be above about 25% of the total level of fat deposited as coating. For example, if about 10% of fat was added on top of the surface of the kibble, the desired level of surface fat may be at least about 2.5%, or even about 5% or more, with the remainder of the fat soaking into the kibble or other coating layers or both.
- a kibble for the most part will consist of ingredients which may be described as substantially proteinaceous or substantially farinaceous.
- a proteinaceous ingredient can generally be defined as any material having a protein content of at least about 15% by weight; whereas, a farinaceous material has a protein content substantially below this and has a major fraction of starchy or carbohydrate containing materials.
- proteinaceous materials which are typically used in commercial pet foods include vegetable protein meals, such as soybean, cottenseed, or peanut meals, animal proteins such as casein, albumin, whey, including dried whey, and meat tissue including fresh meat as well as rendered or dried "meals” such as fish meal, poultry meal, meat meal, meat and bone meal, enzymatically-treated protein hydrolysates, and the like.
- animal proteins such as casein, albumin, whey, including dried whey, and meat tissue including fresh meat as well as rendered or dried "meals” such as fish meal, poultry meal, meat meal, meat and bone meal, enzymatically-treated protein hydrolysates, and the like.
- Other types of proteinaceous materials include microbial protein such as yeast, and other types of protein, including materials such as wheat gluten or corn gluten. Yeasts may also add flavor; wheat or corn gluten may also act as texturizing agents and can be used to increase product porosity.
- Examples of typical farinaceous materials include enzymatic farinaceous materials, grains such as corn, maize, wheat, sorghum, barley, and various other grains which are relatively low in protein. Numerous other materials could be added to a kibble which do not necessarily fall into either category (proteinaceous or farinaceous), including carbohydrates and legumes, such as alfalfa or soy. Typical formulae for kibbles are well known in the art.
- the compositions of the invention generally may include vitamins, minerals, and other additives such as flavorings, preservatives, emulsifiers and humectants.
- the nutritional balance including the relative proportions of vitamins, minerals, protein, fat and carbohydrate, is determined according to dietary standards known in the veterinary and nutritional art.
- Dry additives refer to any additives that comprise less than 40% of a polar solvent (such as water) by weight of the dry additive at the time it is applied to a food.
- exemplary additives that may be provided in dry form include various flavors, such as meat and cheese flavorings; meat solids and dry animal digest; herbs; dry palatants; hydrolyzed (by chemical or enzyme) vegetable proteins; minerals; prebiotics; probiotics; encapsulated compounds; nutrients; pharmaceutical or homeopathic compounds; colorants; and combinations thereof.
- Other examples of dry additives include Bakery yeast or Brewer's yeast, which comprise dried pulverized cells of a yeast of the genus Saccharomyces (usually S. cerevisiae), often used in brewing, Torula yeast, and various yeast extracts.
- Liquid additives refer to any additives that comprise at least 40%, at least 50%, at least 60%, or up to 90% of a polar solvent (such as water) by weight of the liquid additive composition.
- Liquid additives include dry additives which have been dissolved, suspended, or submersed in a polar solvent prior to application to a food.
- Exemplary palatants that may be provided in liquid form include digests of animal origin; vitamins; amino acids; proteins or protein hydrolysates, including proteins or protein hydrolysates of vegetable origin, proteins or protein hydrolysates of animal origin, and synthetic proteins; other nutrients; yeast suspensions; flavor compositions; acidulents; dye compositions; broths; antioxidants; and combinations thereof.
- the kibbles comprising the bacteria of the present invention may also comprise a prebiotic.
- prebiotic includes substances or compounds that are fermented by the intestinal flora of the pet and hence promote the growth or development of bacteria in the gastro-intestinal tract of the pet at the expense of pathogenic bacteria. The result of this fermentation is a release of fatty acids, in particular short-chain fatty acids in the colon. This has the effect of reducing the pH value in the colon.
- suitable prebiotics include oligosaccharides, such as inulin and its hydrolysis products commonly known as fructooligosaccharides, galacto-oligosaccarides, xylo-oligosaccharides or oligo derivatives of starch.
- the prebiotics may be provided in any suitable form.
- the prebiotic may be provided in the form of plant material which contains the fiber. Suitable plant materials include asparagus, artichokes, onions, wheat or chicory, or residues of these plant materials.
- the prebiotic fiber may be provided as an inulin extract, for example extracts from chicory are suitable.
- Suitable inulin extracts may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftiline.”
- the inulin may be provided in the form of Raftiline (g) ST which is a fine white powder containing about 90% to about 94% by weight of inulin, up to about 4% by weight of glucose and fructose, and about 4% to about 9% by weight of sucrose.
- the fiber may be in the form of a fructooligosaccharide such as obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftilose.”
- the inulin may be provided in the form of Raftilose (g) P95.
- the fructooligosaccharides may be obtained by hydro lyzing inulin, by enzymatic methods, or by using micro-organisms.
- a suitable process is extrusion cooking, although baking and other suitable processes may be used. If a prebiotic is used, the prebiotic may be mixed with the other ingredients of the dried kibble prior to processing.
- Kibbles may contain other active agents such as long chain fatty acids and zinc.
- Suitable long chain fatty acids include alpha-linoleic acid, gamma linolenic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid.
- Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid.
- Borage oil, blackcurrent seed oil, and evening primrose oil are suitable sources of gamma linolenic acid.
- Safflower oils, sunflower oils, corn oils, and soy bean oils are suitable sources of linoleic acid. These oils may also be used in the coating substrates referred to above.
- Zinc may be provided in various suitable forms, for example as zinc sulfate or zinc oxide. Further, many ingredients commonly used in pet foods are sources of fatty acids and zinc. It has been observed that the combination of chicory, as a source of prebiotic, with a linoleic-acid rich oil, such as soy bean oil, provides unexpected benefits, suggestive of a synergistic effect.
- AHC-7 probiotic is expected to be in direct contact with kibble raw material and other coatings, such as flavoring agents, fat, palatant, and any other ingredient applied externally for improvement of texture like glycerin or emulsifiers.
- other coatings such as flavoring agents, fat, palatant, and any other ingredient applied externally for improvement of texture like glycerin or emulsifiers.
- the samples comprised AHC-7 probiotic and one coating component, which comprised either chicken fat, dry palatant (SPF 336) or glycerin.
- Sample 1 was a mixture of AHC-7 raw material (AHC-7 raw material comprised AHC-7 (probiotic) and maltodextrin (carrier) in an amount sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g) and palatant 336 (ratio approximately 1 :295).
- Sample 2 was a mixture of AHC-7 raw material and chicken fat containing antioxidant (ratio approximately 1 :1086).
- Sample 3 was a mixture of AHC-7 raw material and glycerin (ratio approximately 1 :2090).
- each Sample (1, 2 and 3) four separate sample sets (four for Sample 1, four for Sample 2, and four for Sample 3), comprising 50ml plastic tubes loaded with lOg of Sample each, were prepared for four pull times.
- the Samples (1 ,2 and 3) in a plastic tube were mixed thoroughly on a vortex type of mixer at room temperature and each tube was later sealed using a plastic cap.
- Samples 1, 2 and 3 (4 tubes for each of the samples) were stored at 23 °C (representative of typical room/store temperature) to assess stability of AHC-7 in the presence of other coating components.
- lOg of Sample that was placed in a plastic tube was used at the respective pull time.
- AHC-7 probiotic loss in Samples 1, 2 and 3 at 23 °C is shown in FIG. 2.
- the AHC-7 loss is measured as delta between initial AHC-7 count (cfu/g) and AHC-7 count at respective pull (cfu/g).
- the AHC-7 count is expressed as log count.
- the results show that AHC-7 was very stable when in direct contact with palatant (Sample 1) and chicken fat (Sample 2). However, AHC-7 showed rapid loss when in direct contact with glycerin (Sample 3).
- the data demonstrates susceptibility of AHC-7 when in contact with glycerin and good stability when in presence of fat and dry palatant.
- Sample 4 was a mixture of AHC-7 raw material (AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)) added sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g) and chicken fat containing antioxidant (ratio approximately 1 :1086).
- Sample 5 was a mixture of AHC-7 raw material and glycerin (ratio approximately 1 :2090).
- AHC-7 probiotic loss in Samples 4 and 5 at 40°C is shown in FIG. 3.
- AHC-7 was very stable when in direct contact with chicken fat (Sample 4) at higher temperature of 40°C for 29 days.
- AHC-7 showed rapid loss when in direct contact with glycerin (Sample 5).
- the loss rate appeared to be greater at higher temperature (40°C) (Sample 5) compared to 23 °C (Sample 3).
- the data demonstrates susceptibility of AHC-7 when in contact with glycerin and good stability when in the presence of fat.
- EXAMPLE 3 To determine if coating has an effect on probiotic stability, various samples were prepared with different kibble coatings. First kibble was produced by extrusion of ingredients listed in TABLE 1 which delivered a kibble with a fat and protein content of 13% and 28% respectively. For kibble making, the dry ingredients (listed in TABLE 1) were blended in batches of 1000 kg for around 20 min using a Hobart® blender (model V-1401 ; Hobart, Troy, OH) to achieve reasonable homogeneity in the blend prior to processing.
- Hobart® blender model V-1401 ; Hobart, Troy, OH
- the blend of ingredients was transferred to a pre-conditioner cylinder, where the materials were mixed at 95 °C for 3 min with sufficient steam/water (approximately 21 % water) to partially gelatinize starches and soften and hydrate all ingredients.
- the hydrated blend of ingredients was then extruded with a single screw extruder, with a barrel temperature ranging from 90°C to 140°C across the different extruder barrel zones (1-6). The diameter of the die used to make this product was 0.28". Kibbles were dried to a final moisture content from 2.5% to 3.5%, and the water activity (Aw) was approximately 0.2.
- the bulk density of the kibbles prior to the application of the coatings was 360 g/lt.
- the components of the kibble are shown in TABLE 1
- each sample group comprised of 30 grams of coated kibble.
- a fat layer (not more than 6% by total weight of coated kibble) comprising a blend of 50% chicken fat, 50% beef tallow and having a melting temperature typically of 35°C.
- a dry blend layer was applied to the fat-coated surface of the kibble.
- This blend comprised about 1.2% of palatant (SPF 336) and about 0.02% of AHC-7 raw material (AHC-7 raw material comprised AHC-7 (probiotic) and maltodextrin (carrier) in an amount sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g).
- the second layer was added after the first fat layer.
- the second layer was applied after the first layer by using a single pass through mixer with multiple delivery ports.
- the temperature of the fat layers is about 10°C higher than the melting point to ensure no problems during pumping and handling and to ensure maximum absorption into the kibble.
- a fat layer comprising a blend of 49% chicken fat, 49% beef tallow, and 2% of a emulsifier (Trancendim® 180, Caravan Ingredients, Lenexa, KS) to obtain a fat layer concentration of about 5% by weight of the coated kibble.
- the emulsifier used has a melting temperature of between 56°C - 68°C and comprises a ratio of monoglycerides to diglycerides of from about 5:1 to about 25:1 (average ratio approximately 12:1).
- a dry blend layer was applied to the fat-coated surface of the kibble.
- This blend comprised of about 1.2% of palatant (SPF 336) and about 0.02% of AHC-7 raw material (AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)) added sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g).
- AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)
- This application resulted in AHC-7 raw material concentration of about 0.02% by weight of the coated kibble, giving an initial AHC-7 concentration of 10 8 cfu/g.
- the second layer is added after the first fat layer.
- the second layer was applied after the first layer by using a single pass through mixer with multiple delivery ports.
- the temperature of the fat layers is about 10°C higher than the melting point to ensure no problems during pumping and handling and to ensure maximum absorption into the kibble.
- Sample Group 8 after drying, the kibbles were spray-coated with a layer of glycerin (Chemical Division, P&G, Cincinnati, OH) at 35°C to 50°C to obtain a concentration of external glycerin of 2.5% by weight of the coated kibble.
- a layer of fat comprising a blend of 50% chicken fat and 50% beef tallow was applied to the glycerin-coated surface of the kibble. This application resulted in a fat layer concentration of about 5% by weight of the coated kibble.
- a dry blend layer was applied to the fat-coated surface of the kibble. This blend comprised of about 1.2% of palatant (SPF 336) and about 0.02% of AHC-7 raw material (AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)) added sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g).
- AHC-7 raw material concentration of about 0.02% by weight of the coated kibble, giving an initial AHC-7 concentration of 10 8 cfu/g.
- the second layer is added after the first fat layer.
- the second layer was applied after the first layer by using a single pass through mixer with multiple delivery ports.
- the temperature of the fat layers is about 10°C higher than the melting point to ensure no problems during pumping and handling and to ensure maximum absorption into the kibble.
- the finished kibbles for Sample Groups 6, 7 and 8 were placed in open petri dishes and incubated in 25°C desiccators of different relative humidities (RHs) for 1 month.
- desiccator RH salt slurry Aw x 100%.
- FIG. 4 The affect of the various coatings used in Sample Groups 6, 7 and 8 on AHC-7 stability is plotted in FIG. 4.
- the data in FIG. 4 shows that the AHC-7 is highly stable with and without the presence of the Trancendim® 180 emulsifier in the fat (Sample Groups 6 & 7).
- the external layer of glycerin proved to be detrimental to AHC-7 stability, as shown by the decreased amount of AHC-7 probiotic levels in Sample Group 8.
- the data in FIG. 4 also shows that the AHC-7 probiotic may be detected after a 1 -month incubation period at Aw's as high as 0.43. However, this does not suggest that the AHC-7 probiotic is stable at such high Aw's for a prolonged period of time. It is possible that the AHC-7 probiotic may rapidly die with time under these conditions.
- glycerin incorporated into a kibble had a detrimental effect on the stability of coated AHC-7 the following samples were prepared, the components of which are listed in TABLE 4.
- First kibble was produced by extrusion of ingredients listed in TABLE 1 which delivered a kibble with a fat and protein content of 13% and 28% respectively.
- the dry ingredients (listed in TABLE 4) were blended in batches of 1000 kg for around 20 min using a Hobart® blender (model V-1401 ; Hobart, Troy, OH) to achieve reasonable homogeneity in the blend prior to processing.
- glycerin was used as a plasticizer and was pumped directly into the pre-conditioner cylinder, where it is incorporated into the dough.
- the level of glycerin added internally to the kibble was 9%.
- the materials were mixed at 95 °C for 3 min with sufficient steam/water (approximately 21 % water) to partially gelatinize starches and soften and hydrate all ingredients.
- the hydrated blend of ingredients was then extruded with a single screw extruder, with a barrel 5 temperature ranging from 90°C to 140°C across the different extruder barrel zones (1-6).
- the diameter of the die used to make the kibbles was 0.28".
- Example Groups 9 to 12 were coated similarly to Sample Group 6 in TABLE 2.
- Each 5 Sample Group comprised 30 grams of kibble (at average density of 300 to 375 g/L)
- the kibbles were spray coated with a fat layer no more than 6% by weight of the coated kibble, comprising a blend of 50% chicken fat, 50% beef tallow and having a melting temperature typically of 35°C. After the kibbles were coated with the fat
- a dry palatant layer was applied to the fat-coated surface of the kibble.
- This blend comprised about 1.2% of palatant (SPF 336) and about 0.02% of AHC-7 raw material (AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)) added sufficient enough to achieve target AHC-7 concentration of around 10 11 cfu/g).
- AHC-7 raw material is AHC-7 (probiotic) and maltodextrin (carrier)
- the second layer is added after the first fat layer.
- the second layer is applied after the first one by using a single pass through mixer with multiple delivery ports.
- the temperature of the fat layers is about 10°C higher than the melting point to ensure no problems during pumping and handling and to ensure maximum absorption into the kibble.
- Sample Groups 13, 14 and 15 were made on a small scale extruder.
- the dry ingredients (listed in Table 6) were blended in batches of 50 kg for around 10 min using a Hobart® blender (model HL-600; Hobart, Troy, OH) to achieve reasonable homogeneity in the blend prior to processing.
- the blend of ingredients was transferred to a pre-conditioner cylinder, where the materials were mixed at 95 °C for 3 min with sufficient steam/water (approximately 21% water) to partially gelatinize starches and soften and hydrate all ingredients.
- the hydrated blend of ingredients was then extruded with a twin screw extruder, with a barrel temperature ranging from 90°C to 140°C across the different extruder barrel zones (1-6).
- the diameter of the die used to make this product was 0.28". Kibbles were dried to a final moisture content from 2.5% to 3.5%, and the water activity (Aw) was approximately 0.2. The bulk density of the kibbles prior to the application of the coatings was 350 g/lt. The components of the kibble are shown in TABLE 6. Sample Groups 13, 14 and 15 had similar dry kibble chassis except for the presence of glycerin at 3% and 5% internally in Sample Groups 14 and 15. The dry kibbles from the extruder (900 to 1200 g) were placed in a blender (Kitchen Aid, Heavy duty, Benton Harbor, Michigan USA), which was set on a slow setting (setting 2).
- Chicken fat was warmed up before being loaded on kibble and AHC-7 was mixed with it, while the chicken fat was mechanically stirred just before loading.
- the AHC-7 through fat (6% of coated kibble weight) was loaded on kibble (target AHC-7 count of 10 7 cfu/g) through spray nozzle assembly equipped with peristaltic pump (Cole-Parmer, Chicago, USA), which allowed for a uniform spray of fat containing AHC-7 on the kibbles, which were slowly rotated in a blender (setting 2) to achieve uniform deposition of fat on the kibbles.
- Dry palatant plus sodium hexametaphosphate (1.6% of coated kibble weight) was added slowly on top of the kibbles sprayed with fat.
- Sample Groups 13, 14 and 15 were evaluated with respect to AHC-7 loss.
- the Sample Groups were transferred to paper bags and sealed using paper and plastic tape.
- the paper bags were stored in a constant condition chamber at 40°C and 75% Relative humidity condition for 15 days.
- the Sample Groups were pulled at 0, 4, 10 and 15 days intervals and assessed for AHC-7 by plate count method. The results are shown in FIG. 6.
- the AHC-7 loss for Sample Groups without internal glycerin (Sample Group 13) and with internal glycerin at two different levels (Sample Groups 14 and 15) were not significantly different from each other (P > 0.05).
- Example 4 had kibble formulation containing corn and chicken by product meal (CBPM), whereas example 5 had kibble formulation with no corn and no chicken by product meal), when glycerin is added internally there is little to no impact on AHC-7 loss.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Feed For Specific Animals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14872178.0A EP3082450A4 (en) | 2013-12-20 | 2014-12-22 | Pet food composition having probiotic bifidobacterium animalis |
RU2016129485A RU2016129485A (en) | 2013-12-20 | 2014-12-22 | COMPOSITION OF FOOD FOR PETS CONTAINING PROBIOTICS BIFIDOBACTERIUM ANIMALIS |
JP2016540543A JP2017501701A (en) | 2013-12-20 | 2014-12-22 | Pet food composition with probiotic Bifidobacterium animalis |
CN201480069889.7A CN106659197B (en) | 2013-12-20 | 2014-12-22 | Pet food composition with probiotic bifidobacterium pseudolongum |
CA2933189A CA2933189A1 (en) | 2013-12-20 | 2014-12-22 | Pet food composition having probiotic bifidobacterium animalis |
AU2014368875A AU2014368875A1 (en) | 2013-12-20 | 2014-12-22 | Pet food composition having probiotic bifidobacterium animalis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/136,528 US20150173397A1 (en) | 2013-12-20 | 2013-12-20 | Pet food composition having probiotic bifidobacterium animalis |
US14/136,528 | 2013-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015095881A1 true WO2015095881A1 (en) | 2015-06-25 |
Family
ID=53398658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/071962 WO2015095881A1 (en) | 2013-12-20 | 2014-12-22 | Pet food composition having probiotic bifidobacterium animalis |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150173397A1 (en) |
EP (1) | EP3082450A4 (en) |
JP (1) | JP2017501701A (en) |
CN (1) | CN106659197B (en) |
AU (1) | AU2014368875A1 (en) |
CA (1) | CA2933189A1 (en) |
RU (1) | RU2016129485A (en) |
WO (1) | WO2015095881A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210010242A (en) * | 2019-07-19 | 2021-01-27 | 유한회사 비피코리아 | Solid lactic acid bacteria for companion animal and manufacturing method thereof |
EP4014750A1 (en) | 2020-12-17 | 2022-06-22 | Tereos Starch & Sweeteners Europe | Croquettes for pets and method for preparing them |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
AU2015293840B2 (en) * | 2014-07-24 | 2019-06-13 | Mars Incorporated | Long-lasting pet food |
MX2017013715A (en) | 2015-04-28 | 2018-03-02 | Mars Inc | Process of preparing a sterilized wet pet food product. |
FI20155330A (en) * | 2015-05-06 | 2016-11-07 | Betulium Oy | feed composition |
CN107549103A (en) * | 2017-09-25 | 2018-01-09 | 镇宁自治县会权特种养殖有限公司 | A kind of method of the meat masked civet of artificial feeding high-quality |
AU2021220800A1 (en) * | 2020-02-10 | 2022-07-07 | Native Microbials, Inc. | Microbial compositions and methods of use for canine enteropathy and dysbiosis |
BE1028970B1 (en) * | 2020-12-29 | 2022-08-01 | Fides Petfood Nv | PRECISION EXTRUSION PROCESS FOR PRODUCING DRY FEED PELLETS FOR DOGS AND/OR CATS AND PELLETS OBTAINED THEREOF |
CN115305210A (en) * | 2021-05-06 | 2022-11-08 | 江苏恒丰强生物技术有限公司 | Method for culturing chicken-derived bifidobacterium pseudolongum and application thereof |
CN113940395B (en) * | 2021-11-17 | 2023-05-23 | 西南科技大学 | Preparation method of probiotic preparation for piglets |
FR3135876B3 (en) * | 2022-05-25 | 2024-05-24 | Nestle Sa | Compositions and methods for dehydrated pet food blends |
WO2024073025A1 (en) * | 2022-09-30 | 2024-04-04 | Mars, Incorporated | Animal food compositions with improved palatability and customizability, and methods for preparing the same |
EP4344552A1 (en) * | 2022-09-30 | 2024-04-03 | Mars, Incorporated | Animal food compositions with improved palatability, and methods for preparing the same |
EP4344553A1 (en) * | 2022-09-30 | 2024-04-03 | Mars, Incorporated | Animal food compositions with improved customizability, and methods for preparing the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100266727A1 (en) * | 2007-11-07 | 2010-10-21 | Encoate Holdings Limited | Stabilisation of dried biological material |
US8034601B2 (en) * | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US20130122154A1 (en) * | 2011-11-14 | 2013-05-16 | The Procter & Gamble Company | Palatable Pet Foods and Methods for Improving the Palatability of Pet Foods |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3883672A (en) * | 1974-06-12 | 1975-05-13 | Quaker Oats Co | Method of making a dry type pet food having a meat-like texture and composition thereof |
US4039689A (en) * | 1976-02-03 | 1977-08-02 | The Quaker Oats Company | Soft dry pet food product and process |
US4910038A (en) * | 1989-01-23 | 1990-03-20 | Huntington Hyde Ltd., Inc. | Pet food and method of preparation |
DE29724815U1 (en) * | 1997-01-09 | 2004-07-22 | Société des Produits Nestlé S.A. | Cereal product containing probiotics |
MXPA02002430A (en) * | 1999-09-07 | 2002-07-02 | Nestle Sa | Method for improving the skin and coat of pets. |
EP1344458A1 (en) * | 2002-03-12 | 2003-09-17 | Société des Produits Nestlé S.A. | Probiotic delivery system |
US20050181097A1 (en) * | 2002-09-16 | 2005-08-18 | Mars, Inc. | Nutritionally complete pet food and method of feeding and manufacturing same |
US20100233347A1 (en) * | 2009-03-13 | 2010-09-16 | Uhrhan Richard B | Food compositions having a realistic meat-like appearance, feel, and texture |
US20100303951A1 (en) * | 2009-05-28 | 2010-12-02 | Gregory Dean Sunvold | Delivering an Active Ingredient in Pet Food |
US20110027420A1 (en) * | 2009-07-31 | 2011-02-03 | Haile Mehansho | Moisture migration reduction layer for a food product |
US8691303B2 (en) * | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
US10104903B2 (en) * | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
JP5431597B2 (en) * | 2010-01-22 | 2014-03-05 | ザ・アイムス・カンパニー | Method for producing pet food in the form of a coated kibble |
EP2449887B1 (en) * | 2010-11-05 | 2016-01-06 | Nestec S.A. | Method for preparing pet food containing probiotic micro-organisms |
-
2013
- 2013-12-20 US US14/136,528 patent/US20150173397A1/en not_active Abandoned
-
2014
- 2014-12-22 RU RU2016129485A patent/RU2016129485A/en not_active Application Discontinuation
- 2014-12-22 JP JP2016540543A patent/JP2017501701A/en active Pending
- 2014-12-22 EP EP14872178.0A patent/EP3082450A4/en not_active Withdrawn
- 2014-12-22 CN CN201480069889.7A patent/CN106659197B/en active Active
- 2014-12-22 CA CA2933189A patent/CA2933189A1/en not_active Abandoned
- 2014-12-22 AU AU2014368875A patent/AU2014368875A1/en not_active Abandoned
- 2014-12-22 WO PCT/US2014/071962 patent/WO2015095881A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034601B2 (en) * | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US20100266727A1 (en) * | 2007-11-07 | 2010-10-21 | Encoate Holdings Limited | Stabilisation of dried biological material |
US20130122154A1 (en) * | 2011-11-14 | 2013-05-16 | The Procter & Gamble Company | Palatable Pet Foods and Methods for Improving the Palatability of Pet Foods |
Non-Patent Citations (1)
Title |
---|
See also references of EP3082450A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210010242A (en) * | 2019-07-19 | 2021-01-27 | 유한회사 비피코리아 | Solid lactic acid bacteria for companion animal and manufacturing method thereof |
KR102270024B1 (en) | 2019-07-19 | 2021-06-30 | 유한회사 비피코리아 | Solid lactic acid bacteria for companion animal and manufacturing method thereof |
EP4014750A1 (en) | 2020-12-17 | 2022-06-22 | Tereos Starch & Sweeteners Europe | Croquettes for pets and method for preparing them |
FR3117738A1 (en) | 2020-12-17 | 2022-06-24 | Tereos Starch & Sweeteners Europe | KIBBLES FOR PETS AND METHOD FOR PREPARING THE SAME |
Also Published As
Publication number | Publication date |
---|---|
RU2016129485A (en) | 2018-01-25 |
CN106659197A (en) | 2017-05-10 |
JP2017501701A (en) | 2017-01-19 |
CN106659197B (en) | 2021-10-08 |
EP3082450A4 (en) | 2017-07-12 |
EP3082450A1 (en) | 2016-10-26 |
AU2014368875A1 (en) | 2016-07-21 |
CA2933189A1 (en) | 2015-06-25 |
US20150173397A1 (en) | 2015-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150173397A1 (en) | Pet food composition having probiotic bifidobacterium animalis | |
US11510424B2 (en) | Pet food compositions including probiotics and methods of manufacture and use thereof | |
Sugiharto et al. | Recent advances in fermented feeds towards improved broiler chicken performance, gastrointestinal tract microecology and immune responses: A review | |
JP6253737B2 (en) | Preference pet food and method for improving pet food preference | |
RU2254772C2 (en) | Method for increasing activity of aging domestic animals | |
EP1887854B1 (en) | Methods for enhancing palatability of compositions for animal consumption | |
EP2334196B1 (en) | Animal feed kibble with protein-based core and related methods | |
CA2782052C (en) | Methods of use of probiotic lactobacilli for companion animals | |
WO2016019017A1 (en) | Animal feed compositions and feed additives | |
CN105410365B (en) | A kind of feed addictive of alternative antibiotic and its application | |
US7318920B2 (en) | Low water activity nutritional product having beneficial microbial and high oil content | |
US20220117263A1 (en) | Pet supplements containing a cannabinoid | |
US20100028483A1 (en) | Solid edible product for a pet | |
JP2002262779A (en) | Sorbic acid material as feed additive for raising agricultural livestock | |
US20210298328A1 (en) | Pet food products comprising oligosaccharides and methods of use | |
EP3698648A1 (en) | Allulose pet food | |
US20240100115A1 (en) | Compositions and methods for digestive health in an feline | |
CN110521870A (en) | A kind of feed for pet and its production technology | |
MXPA01005110A (en) | Method for increasing pet activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14872178 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2933189 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016540543 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014872178 Country of ref document: EP |
|
WD | Withdrawal of designations after international publication | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2014872178 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016129485 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014368875 Country of ref document: AU Date of ref document: 20141222 Kind code of ref document: A |